|
Statement
| 1.Date of the shareholders meeting resolution:2022/06/22
2.Name and title of the director with permission to engage in competitive
conduct:
Director:Huang,Chun-Mu
Director:HUA ENG WIRE&CABLE CO., LTD Representative： Liou, Xiu-Mei
Director:TONGHUA DONGBAO Pharmaceutical CO., LTD. Representative:
Leng,Chun-Sheng
Director:TONGHUA DONGBAO Pharmaceutical CO., LTD. Representative:
Zhang Wen-Hai
Director:Yanben Investment Co., Ltd.
Director:Baijue Investment Co., Ltd.
Independent Director:Zeng,Hui-Jin
Independent Director:Liu,Mei-An
Independent Director:Chen,Rui-Xin
3.Items of competitive conduct in which the director is permitted to engage:
The same with the scope of business of the Company.
4.Period of permission to engage in the competitive conduct:
During the term of office as a director of the company
The same with the scope of business of the Company.
5.Circumstances of the resolution (please describe the results of voting in
accordance with Article 209 of the Company Act):
Proposal was approved after voting:
(approval votes： 51,312,783, disapproval votes： 38,055, invalid votes：
0, abstention votes/no votes： 5,060,764, total votes： 56,411,602)
6.If the permitted competitive conduct belongs to the operator of a mainland
China area enterprise, the name and title of the directors
(if it is not the operator of a Mainland-area enterprise, please enter
"N/A" below):
Director:TONGHUA DONGBAO Pharmaceutical CO., LTD. Representative:
Leng,Chun-Sheng
Director:TONGHUA DONGBAO Pharmaceutical CO., LTD. Representative:
Zhang Wen-Hai
7.Company name of the mainland China area enterprise and the director's
position in the enterprise:
Director:TONGHUA DONGBAO Pharmaceutical CO., LTD. Representative:
Leng,Chun-Sheng/Chairman and General Manager of TONGHUA DONGBAO
Pharmaceutical CO.
Director:TONGHUA DONGBAO Pharmaceutical CO., LTD. Representative:
Zhang Wen-Hai/Deputy General Manager of TONGHUA DONGBAO
Pharmaceutical CO.
8.Address of the mainland China area enterprise:
Tonghua Dongbao Pharmaceutical Co., Ltd., Address: Dongbao New Village,
Tonghua County, Jilin Province
9.Operations of the mainland China area enterprise:
The company is mainly engaged in the research and development, production
and sales of Biopharmaceuticals,TCM And Chemical Medicines in diabetes
and endocrine therapy.
10.Impact on the company's finance and business:None.
11.If the directors have invested in the mainland China area enterprise,
the monetary amount of the investment and their shareholding ratio:
Director Tonghua Dongbao Pharmaceutical Co., Ltd., the investment targets
in mainland China are as follows:
(1) Tonghua Dongbao Environmental Protection Building Materials (Shares)
Company,the investment amount is RMB 95,088,000, and the shareholding
ratio is 95.09%.
(2) Changchun Dongbao Pharmaceutical Co., Ltd. The investment amount is RMB
9,500,000,and the shareholding ratio is 95%.
(3) Beijing Dongbao Biotechnology Co., Ltd., the investment amount is RMB
100,366,451.68, and the shareholding ratio is 100%.
(4) Tonghua Dongbao Jinhongji Real Estate Development Co., Ltd. Tonghua
County First Branch, the investment amount is RMB 25,500,000, and the
shareholding ratio is 97.59%.
(5) Tonghua Zixing Bio-Pharmaceutical Co., Ltd., the investment amount is
RMB 10,000,000,and the shareholding ratio is 100%.
(6) Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., the investment
amount is RMB 100,000,000, and the shareholding ratio is 100%.
12.Any other matters that need to be specified:None
|
